# Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Study · id `cardio:ct-nct02586155` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02586155](<https://clinicaltrials.gov/study/NCT02586155>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02586155

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2425 participants.

## Technical summary

Registry record NCT02586155. Randomized; triple masking; primary purpose prevention. Start 2015-11 (actual); primary completion 2020-11-30 (actual). Results posted on 2021-08-20.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 2425 participants (enrolled count; ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Started: 2015-11 (actual) (ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Primary completion: 2020-11-30 (actual) (ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Completion: 2021-06-21 (actual) (ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Results first posted: 2021-08-20 (ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Countries: Argentina; Australia; Belgium; Bulgaria; Croatia; Germany; Hungary; Israel; Mexico; Netherlands; Poland; Russia; Serbia; Slovakia; Taiwan (ClinicalTrials.gov record NCT02586155, source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02586155-2021-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD
- Acronym: BETonMACE
- Condition: Diabetes Mellitus, Type 2
- Condition: Coronary Artery Disease
- Intervention (Drug): Apabetalone
- Intervention (Drug): Placebo
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Rosuvastatin
- Lead sponsor: Resverlogix Corp
- Lead sponsor class: INDUSTRY
- Collaborator: PPD Development, LP
- Collaborator class: INDUSTRY
- Collaborator: ICON plc
- Collaborator class: INDUSTRY
- Collaborator: Medidata Solutions
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Resverlogix Corp (`cardio:org-resverlogix-corp`)
- Registry lists this organization as a collaborator: PPD Development, LP (`cardio:org-ppd-development-lp`)
- Registry lists this organization as a collaborator: ICON plc (`cardio:org-icon-plc`)
- Registry lists this organization as a collaborator: Medidata Solutions (`cardio:org-medidata-solutions`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial (`cardio:pubmed-32219359`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial (`cardio:pubmed-34158057`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a4db6173f9f1feabc441b359fdfdffd8449ded5d4b75f67454502e8adf0779a6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
